Fred is a Managing Director at TPG (Texas Pacific Group) Ventures. He also retains a position as a Professor of Cellular and Molecular Pharmacology at the University of California, San Francisco. Fred also serves as a member of the boards of GenomicHealth, XDx, Kemia, Five Prime Therapeutics and Matrix Pharmaceuticals. He is also a member of the Investment Committee of the Board of Quintiles Transnational. He received his M.D. from Stanford in 19...
more
Fred is a Managing Director at TPG (Texas Pacific Group) Ventures. He also retains a position as a Professor of Cellular and Molecular Pharmacology at the University of California, San Francisco. Fred also serves as a member of the boards of GenomicHealth, XDx, Kemia, Five Prime Therapeutics and Matrix Pharmaceuticals. He is also a member of the Investment Committee of the Board of Quintiles Transnational. He received his M.D. from Stanford in 1984, his D.Phil. from Oxford as a Rhodes Scholar in 1980 and his B.S. in 1978 from Yale University. Fred has been a member of the faculty of UCSF since 1986 and is best known for his work on protein structure and the conformational basis of prion disease.
less
